RenovoRx (RNXT) Shares Climb +62% on Record Revenue and Trial Enrollment
Key Takeaways
- RenovoRx shares climbed about 62% over the trailing 30 days, from $0.8653 at the July 17, 2026 close to $1.40 at the August 14, 2026 close.
- The advance accelerated after record second-quarter revenue of $909,000, up 61% sequentially and 115% year over year, alongside a narrower-than-expected adjusted net loss.
- Management raised full-year 2026 revenue guidance to $3.75 million-$4.25 million, implying year-over-year growth of roughly 241%-286%.
- Enrollment in the Phase III TIGeR-PaC trial in locally advanced pancreatic cancer was completed in August 2026, with topline data expected in the second half of 2027.
- Shares finished near a 52-week high and above the 50-day and 200-day moving averages, supported by elevated trading volume.
A Closer Look at RenovoRx (RNXT) and Its Position
RenovoRx, Inc. is a Mountain View, California-based life sciences company developing targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared catheter system. Its Trans-Arterial Micro-Perfusion (TAMP) platform is designed to deliver chemotherapy agents directly to tumor sites through the arterial wall while limiting systemic exposure. The company generates recurring device revenue from RenovoCath and is advancing intra-arterial gemcitabine (IAG) in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. RenovoCath with gemcitabine holds Orphan Drug Designations for pancreatic and bile duct cancers. Investors follow the stock for commercial adoption metrics, revenue growth, and pivotal clinical-trial progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
RNXT Stock Price Performance Over the Past 30 Days and Quarter
For the 30-day window, RNXT rose 61.8%, from the July 17, 2026 close of $0.8653 to the August 14, 2026 close of $1.40. Trading was range-bound through much of July, with pullbacks toward the $0.85 area before a late-July recovery near $0.96. The breakout arrived in early August, when shares cleared $1.00, followed by double-digit percentage gains on August 13 and August 14 as daily volume expanded above 670,000 shares.
Over the trailing quarter, the stock advanced approximately 64%, from $0.855 on May 14, 2026 to $1.40 on August 14, 2026. The period included a May pullback to $0.7832, a June rebound, and a July consolidation before the catalyst-driven rally in August. From what I see, the technical setup above key moving averages stood out clearly in the data.
Key Catalysts Behind the Recent 30-Day Rally
The most significant catalyst was the second-quarter report released in mid-August. Revenue reached a record $909,000, supported by rising procedures and repeat orders for RenovoCath, while gross margin held near 84%. The company ended the quarter with 21 active commercial cancer centers, up from 16 in May, and reported a total commercial funnel of 63 centers. Management also raised and tightened full-year 2026 revenue guidance.
Clinical news reinforced the move: RenovoRx completed enrollment in the Phase III TIGeR-PaC trial, with investigators notified on August 7, 2026. After the results, several sell-side firms maintained buy ratings on the stock, with published price targets ranging from $3 to $14. The combination of improving commercial fundamentals, a pivotal-trial milestone, and a technical breakout above $1.00 contributed to the sharp re-rating and the volume surge in mid-August. I’m watching this closely for how the commercial ramp translates into sustained revenue.
Broader Drivers Over the Past Quarter
The broader quarterly narrative has been accelerating commercialization and gradual clinical de-risking. Active commercial centers grew from 8 at the end of 2025 to 21 by June 30, 2026, with management targeting at least 36 active centers by year-end. A $10 million oversubscribed private placement in March strengthened the balance sheet, and cash of approximately $9.5 million at June 30 supports a projected runway into the second half of 2027.
Clinical and scientific updates also expanded the story beyond pancreatic cancer, including peer-reviewed TAMP case studies, a pharmacokinetic sub-study acceptance, and the first RenovoCath treatment in a sarcoma patient in a clinical setting. Management's decision to raise full-year guidance reinforced confidence in the commercial ramp, while trial-site transitions toward commercial use created a clearer path between clinical execution and revenue growth.
What to Watch Next for RNXT
Investors should monitor quarterly revenue updates, particularly whether third-quarter revenue tracks above the second-quarter level as management indicated, and progress toward the 36-active-center target. Clinical execution remains central: trial completion is expected in the first half of 2027, with topline data anticipated in the second half of 2027. Additional data publications, regulatory interactions with the FDA, reimbursement decisions, and expansion beyond pancreatic cancer could also shape sentiment. Key risks include clinical-trial failure or delay, slower site activation, future capital needs, and the volatility typical of small-cap life-science stocks. One thing that stands out is how the guidance raise aligns with the expanding center count.
AI Tools I Rely On for Deeper Analysis
In my research process, I frequently review Tickeron’s AI Trading Bots to evaluate automated strategies that align with evolving market conditions and the specific risk profile of names like RNXT. These tools help surface patterns across hundreds of tickers and timeframes, offering a structured way to cross-check fundamental and technical developments without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RNXT sees MACD Histogram crosses below signal line
RNXT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 47 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for RNXT moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 26 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNXT as a result. In 83 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNXT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RNXT broke above its upper Bollinger Band on August 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for RNXT moved above the 200-day moving average on August 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +30.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNXT advanced for three days, in 198 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 88 of 102 cases where RNXT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. RNXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.496) is normal, around the industry mean (25.929). P/E Ratio (0.000) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (31.250) is also within normal values, averaging (437.043).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement